Stay updated with breaking news from Per Plotnikof. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
18.01.2024 - The trial now progresses into its second part, expected to complete later in 2024. ALK to submit a protocol amendment for Phase 1-2 efficacy trial extension. ALK (ALKB:DC / OMX: ALK B / AKBLF) announced today that it has completed the first part of ...
2024 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 11 January 2024: Silent period 8 February 2024: Annual report 2023 ...
ALK and its Japanese partner Torii Pharmaceutical Co., Ltd. today announced that they have expanded their collaboration and entered into an additional license agreement, granting Torii exclusive...
On Wednesday, 15 November 2023 ALK releases its nine-month interim report 2023. ALK will host a meeting for analysts and institutional investors that day at 1.30pm at which Management will review...
ALK delivers 11% revenue growth with operating profit up 120% in Q2 (unaudited) ALK’s revenue grew by 11% in Q2 2023, driven...